vTv Therapeutics to be Acquired by G42 Healthcare Investments
Ticker: VTVT · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $35 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, healthcare
TL;DR
vTv Therapeutics is getting bought by G42 Healthcare Investments, deal expected to close Q2 2024.
AI Summary
vTv Therapeutics Inc. announced on March 25, 2024, that it entered into a definitive agreement to be acquired by G42 Healthcare Investments Limited. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition aims to accelerate vTv Therapeutics' development of its pipeline, particularly its lead drug candidate, TTP273, for the treatment of type 2 diabetes.
Why It Matters
This acquisition by G42 Healthcare Investments could significantly impact the development and availability of vTv Therapeutics' drug candidates, potentially bringing new treatments to market faster.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a level of uncertainty until the deal is finalized.
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- G42 Healthcare Investments Limited (company) — Acquiring entity
- TTP273 (drug_candidate) — Lead drug candidate for type 2 diabetes
- March 25, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring vTv Therapeutics Inc.?
G42 Healthcare Investments Limited is acquiring vTv Therapeutics Inc.
What is the expected closing timeframe for the acquisition?
The acquisition is expected to close in the second quarter of 2024.
What is vTv Therapeutics' lead drug candidate mentioned in the filing?
vTv Therapeutics' lead drug candidate is TTP273, for the treatment of type 2 diabetes.
On what date was the definitive agreement for the acquisition announced?
The definitive agreement was announced on March 25, 2024.
Are there any specific conditions mentioned for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-03-26 16:35:58
Key Financial Figures
- $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market
- $35 million — d securities ("MVLS") to be at or above $35 million (the "MVLS Requirement"). Nasdaq's noti
Filing Documents
- vtvt-20240325.htm (8-K) — 22KB
- 0001641489-24-000020.txt ( ) — 142KB
- vtvt-20240325.xsd (EX-101.SCH) — 2KB
- vtvt-20240325_lab.xml (EX-101.LAB) — 21KB
- vtvt-20240325_pre.xml (EX-101.PRE) — 12KB
- vtvt-20240325_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On March 25, 2024, The Nasdaq Stock Market LLC ("Nasdaq") notified vTv Therapeutics, Inc. (the "Company") that the Company had regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a listed company's market value of listed securities ("MVLS") to be at or above $35 million (the "MVLS Requirement"). Nasdaq's notice provided that because the Company had regained compliance with the MVLS Requirement, the listing of the Company's common stock on the Nasdaq Capital Market would continue.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer Dated: March 26, 2024